Streetbeat News

Products Services

MRUS

Merus has published two abstracts on the European Society for Medical Oncology Congress (ESMO) 2023 website, highlighting updated interim clinical data from the ongoing phase 1/2 eNRGy trial and Early Access Program (EAP) of the bispecific antibody zenocutuzumab in patients with neuregulin 1 fusion cancer. The ESMO Congress 2023 will take place in Madrid, Spain October 20-24, 2023.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 7:32 am

BNR

Burning Rock has received a breakthrough device designation from China's NMPA for its multi-cancer early detection test. This designation could potentially expedite the development and review process of the test.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 7:24 am

ARVN

PFE

Arvinas and Pfizer will present updated Phase 1/2 data for Vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 7:19 am

ARVN

Arvinas is set to present updated Phase 1/2 trial data for Bavdegalutamide (ARV-110) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 7:17 am

REGN

Regeneron Pharmaceuticals is set to present the latest clinical data from its oncology pipeline at the European Society for Medical Oncology (ESMO) Congress 2023. The data will cover both early- and late-stage cancers.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 7:14 am

LLY

Eli Lilly has announced detailed results from its Phase 3 SURMOUNT-3 clinical trial evaluating Tirzepatide in adults with obesity or overweight with weight-related comorbidities, excluding Type 2 diabetes.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 7:08 am

GE

GE HealthCare has announced the results of a study demonstrating the performance of its Portrait Mobile Continuous Monitoring Solution with patients and care teams in the ward.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 7:02 am

MLTX

MoonLake Immunotherapeutics announced 24-week top-line results from its global Phase 2 MIRA trial for its maintenance treatment with its Nanobody® Sonelokimab. The company is expected to be mentioned as MLTX in the article.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 7:00 am

GOOG

GOOGL

Elon Musk criticized the increasing number of advertisements on Alphabet Inc.-owned YouTube, terming it as 'Ad Creep'. This criticism comes amidst YouTube's decision to limit individual ad control options for creators and adjust its ad format. YouTube also plans to increase the price for YouTube Premium to $13.99 per month.

Portfolio Pulse from Ananya Gairola

October 16, 2023 | 6:58 am

ERJ

HON

Honeywell (HON) has successfully tested an engine using 100% sustainable aviation fuel on an Embraer (ERJ) business jet. This marks a significant step towards sustainable aviation.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 6:52 am